For instance, the HybridDC nanovaccine, incorporating CCR7, tumor antigens, and costimulatory molecules, enhances precise targeting to lymphoid tissues, improving antigen delivery and reshaping the tumor immune landscape. The gene discussed is CCR7; the disease is neoplasm.